The Weekly Litigation News Digest is now live. Subscribe now

Amicus Therapeutics competitive analysis

Loading summary...

Explore Amicus Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
Dec 4, 2024Methods Of Treating Fabry Disease In Patients Having A Mutation In The Gla Gene2
Dec 4, 2024Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease3
Nov 13, 2024Use Of Migalostat In Reducing The Risk Of Cerebrovascular Event In Patients With Fabry Disease3
Oct 9, 2024Methods Of Treating Fabry Patients Having Renal Impairment2
Jul 24, 2024Methods Of Treating Fabry Disease In Patients Having A Mutation In The Gla Gene2
Nov 1, 2023Methods Of Treating Fabry Patients Having Renal Impairment1
Oct 25, 2023Treatment Of Patients With Classic Fabry Disease1
Sep 1, 2021Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The Gla Gene2
Apr 22, 2020Dosing Regimens For The Treatment Of Fabry Disease1

Latest PTAB cases involving Amicus Therapeutics

Discover the latest PTAB cases involving Amicus Therapeutics, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Amicus Therapeutics with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
AMICUS THERAPEUTICS - 17 - -
BRAND MURRAY FULLER23 - - -
SANDOZ1191619 -
TEVA PHARMACEUTICALS20916 - 12